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AbstrAct:
The prevalence of xenotropic murine leukemia virus-related virus (XMRV) in human 
population and its involvement in prostate cancer are subjects of ongoing research 
and debate. 22Rv1, which is a human cell line that serves as a common model of 
androgen-independent prostate cancer, was recently reported to carry infectious 
copies of XMRV. 22Rv1 was derived from a prostate cancer xenograft CWR22 that 
was serially passaged in immunodeficient mice. Based on the analysis of the DNA 
from CWR22 and 22Rv1, we present evidence against the presence of XMRV in CWR22 
and, by inference, the tumor, from which CWR22 and 22Rv1 were established. While 
the presence of XMRV in 22Rv1 is likely to be an artifact, it may be a significant 
factor in determining the biological properties of this cell line. This consideration 
warrants additional caution for the interpretation of the relevance of the studies, 
which utilize this popular cell line as a model. It also invites a closer look at the 
sources of viral contamination in xenografts and cultured cells, as well as in the 
experiments that allege the presence of this virus in human cells and populations.
bAckground 
Xenotropic murine leukemia virus-related virus 
(XMRV) is a recently discovered human gammaretrovirus 
that shares a very high degree of homology with murine 
leukemia virus (MLV)[1, 2]. XMRV was first identified in 
samples from prostate cancer patients and was reported 
to be more prevalent in the individuals with mutations in 
RNAse L gene. Subsequent studies reported very high 
incidence of XMRV infection among the individuals 
diagnosed with chronic fatigue syndrome. The same 
studies reported noticeable presence of XMRV among 
apparently asymptomatic individuals, suggesting that 
several percent of the studied control populations may 
be carriers of the virus. Numerous subsequent studies 
significantly differ in their conclusions on the incidence 
of XMRV infection in healthy individuals, as well as 
on its association, if any, with chronic fatigue, prostate 
cancer or RNAse L mutations [3-12]. 
Originally, XMRV was detected in fibroblast and, 
more rarely, hematopoietic cells of prostate cancer 
patients. This is in a sharp contrast with rodent tumors 
caused by murine leukemia virus, where the virus is 
ubiquitously found in the tumor cells. This prompted 
discussions about the role, if any, that the virus might 
have in the etiology of the disease. Later studies did 
report detection of XMRV in cancer epithelial component 
[13], although the causative role of the virus remained 
open to discussion. In this regard, a potentially important 
finding was made when XMRV was detected in a human 
carcinoma cell line 22Rv1[14]. Unlike patient-derived 
samples, this cell lines provides a virtually unlimited 
supply of material for investigation, which greatly 
extends simplicity and reliability of analysis. In addition 
to yielding a concrete example of XMRV presence in 
prostate cancer cells, these findings potentially provided 
an avenue to test the causal link between the virus and 
the transformed phenotype of the cells. For example, the 
proviruses may be tested for the presence of recombinant 
oncogenes, and the genes adjacent to the insertion sites 
and, possibly, affected by the provirus may be tested for 
their involvement in oncogenesis.Oncotarget 2011; 2:  358 - 362 359 www.impactjournals.com/oncotarget
An important pitfall en route to linking the XMRV 
infection and the transformed status of 22Rv1 is that the 
presence of the virus in the cultured cells does not prove 
that the virus was present in the original tumor. The cell 
line was established from a human xenograft that was 
first  serially-passaged  in  immunocompromised  mice 
and then was extensively cultured in vitro. Therefore, 
there is a possibility that the virus was introduced either 
in the mouse host or during culture. The risk of the later 
is underscored by the propensity of XMRV to spread 
between cultured human cell lines [2, 15]. 
Although the original tumor specimen is unavailable 
to us, we decided to investigate whether XMRV is present 
in an early-passage CWR22 xenograft. 
results 
We have obtained a fragment of an early passage 
CWR22 xenograft from the Roswell Park Cancer Institute 
collection, and the 22Rv1 cell line from the laboratory of Dr. 
Gudkov at the same institution. Because misidentification 
of the origin of cultured cells is a common problem, we 
used the analysis of polymorphic sites to confirm that the 
cell line and the xenograft are singeneic. Indeed, every 
single one of the 65 tested polymorphic sites was identical 
between the two DNA samples. 
Next, we designed a PCR strategy that would reliably 
and specifically identify the presence of XMRV DNA in 
genomic samples. The main challenge in this undertaking 
is avoiding cross-reactivity with the endogenous retrovirus 
in human and, especially, mouse genome [16-19], as well 
as with the commonly used retroviral vectors. To this end, 
we took advantage of a characteristic deletion, which sets 
XMRV aside from most endogenous mouse viruses. We 
were able to achieve a robust and specific amplification 
of control XMRV DNA. As is seen on a representative gel 
(Fig. 1A), no product was generated from mouse DNA, 
human DNA from prostate cancer cells, as well as from 
human DNA from a cell line that harbors an integrated 
retroviral vector. As expected, 22Rv1 cells produced a 
strong band. The fragment amplified from 22RV1 cells 
was cloned and sequenced and revealed 100% homology 
with the sequence of XMRV previously identified in these 
cells[14]. The attempts to amplify the fragment from the 
DNA of the CWR22 tumor failed. This is not due to the 
presence of an inhibitor in the tumor DNA: detectable 
signals were obtained from the tumor DNA reconstituted 
with various quantities of XMRV DNA in a plasmid form, 
as well as with the DNA from the 22Rv1 cells (Fig. 1B). 
The absence of the signal in some of the samples, the 
water controls and in the extreme dilutions of the positive 
controls with the tumor DNA confirms the specificity and 
indicates the limits of sensitivity of our procedure. 
To account for the possible differences in the quality 
of the DNA from 22Rv1 and the CWR22 tumor we have 
conducted quantitative real-time PCR, using a pair of 
primers for a fragment of human myogenin promoter as 
an internal control. While the efficiency of amplification 
of the internal control was similar in all samples, 22Rv1 
yielded a robust signal, the signal from the DNA of the 
CWR22 tumor was negligible (at least 370 fold lower than 
in 22Rv1 sample), and the mixture of the two showed the 
expected intermediate result (Fig. 2). 
The sensitivity of our approach cannot rule out that 
some individual cells in the CWR22 tumor carry XMRV. 
However, based on our model dilutions and the prior 
reports that XMRV load in 22Rv1[14], we concluded that 
the virus load in the xenograft is significantly lower that 
one copy per cell. 
discussion 
Our results indicate that XMRV virus has not spread 
in CWR22 tumor before it was removed from the patient 
and serially passaged as a xenograft. The mechanisms of 
oncogenesis previously associated with infection with 
Figure  1:  PCR  amplification  of  XMRV  sequences  from  genomic  DNA  and  model  mixtures.  A. PCR with XMRV-
specific primers was performed on the DNA from human cells infected with an MLV-based vector (“human+vector”), a C57BL/6 mouse 
(“C57BL/6”), uninfected human prostate cancer cells (“human”), 22Rv1 cells (“22Rv1”), CWR22 tumor, and on a 1:2 mix of 22Rv1 and 
CWR22 DNA (“22Rv1:tumor”). B. The indicated model mixtures were created using the DNA from 22Rv1 cell line and CWR22 tumor, 
as well as by spiking CWR22 tumor DNA with appropriately diluted plasmid, which contained a complete XMRV genome. PCR was 
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MLV-like retroviruses include insertional mutagenesis and 
transduction with oncogenes serendipitously incorporated 
into the viral genomes. Both of these mechanisms imply 
the presence of at least one particular copy of the provirus 
in every cancer cell and, therefore, are ruled out by our 
observations of CWR22 xenograft. Although we cannot 
technically rule out that a very small fraction of cells 
in the examined CWR22 xenograft did carry the virus, 
we  find  it  unlikely,  that  a  replication-competent  virus 
would fail to spread in a pool of susceptible cells after 
multiple passages in an immuno-deficient host. Therefore, 
we conclude that, in the most likely scenario, the virus 
was not present in the tumor in the original patient, and 
has been introduced as an artifact later. This conclusion 
raises important questions about the sources of this 
contamination, and invites scrutiny to any other findings 
of the virus in cultured cells. It is important to note that our 
results do not rule out the presence of XMRV in human 
population in general, but bring about the questions about 
the sources of contamination that might have influenced 
the interpretation of results from patient samples.
While this paper was in preparation, another report 
[19] has suggested that XMRV presence in human 
patient samples is an artifact of the PCR techniques used 
to detect the virus . Although the authors of that report 
did not provide the evidence that their own detection 
technique was free of contamination, they mention that 
XMRV-like sequences were found in some of the tested 
inbred mouse strains (apparently, not examined were 
the immunocompromized strains that are typically used 
to harbor human xenografts), and suggest an intriguing 
hypothesis that the XMRV sequences allegedly derived 
from the patients emerged through recombination between 
XMRV from 22Rv1 and some endogenous murine viruses. 
In this regard, it is important to note that the mouse DNA 
used in the current study was derived from a strain, which 
was extensively back-crossed to C57BL/6J background. 
The recent report failed to identify the characteristic 
XMRV sequences in C57BL/6J DNA[19], and the Primer-
BLAST analysis (accessed through http://www.ncbi.nlm.
nih.gov/tools/primer-blast/) indicated that the primer pair 
used in our study lacks targets in the mouse genome.
22Rv1 is a widely-used in vitro model of prostate 
cancer. It has been especially popular as a model of the 
androgen-independent form of the disease. It has been 
a subject of numerous studies that try to identify the 
determinants of the resistance, the ways to overcome it, as 
well as additional potential targets for the therapy of this 
malignancy. Establishment of prostate cancer cell lines that 
retain meaningful properties of the disease is notoriously 
difficult. In this regard, it is important to mention that 
the original tumor and the routinely passed CWR22 
xenografts were androgen-dependent, while the cell 
line was established from a xenograft that recurred after 
castration of the host [20]. The material from the specific 
xenograft immediately prior to the selection for androgen-
independence, as well as from the earliest passages of the 
cell line, is not available to us. At this time, one cannot 
rule out the possibility that XMRV infection played a role 
either in establishment of androgen-independence or in 
adaptation of the cells to culture conditions. Prior analyses 
of proviruses in the 22Rv1 DNA are consistent with the 
presence of multiple copies of unrearranged full-length 
virus in every cell. Oncogenic effects of unrearranged 
MLV are attributable to insertional mutagenesis[21]. In 
this case, insertion of the LTR-encoded promoter underlies 
the high yield of phenotypically-detectable mutations 
[22]. Consequently, the function of the promoter becomes 
a critical determinant of the phenotype of the cell. 
XMRV integration site preferences make it a plausible 
mutagen[23], while the initial analysis of the functional 
organization of the XMRV promoter revealed important 
differences from the classical MLV, including functional 
sites of hormone-regulated transcription factors[24]. If 
the function of the LTR promoter indeed contributes to 
the properties of this cell line, then one may discover 
various dependencies and vulnerabilities in 22Rv1, which 
are related to the regulation of the LTR, but are irrelevant 
to the properties of “real-life” human tumors. We believe 
Figure 2: Detection of XMRV genome by quantitative 
PCR.  Quantitative  PCR  using  XMRV-specific  primers  was 
performed  on  pure  DNA  from  22Rv1  (“22Rv1”)  and  from 
CWR22 xenograft (“tumor”), as well as on a 1:3 mixture of 
the two (“22Rv1/tumor mix”). Amplification of a fragment of 
human myogenin promoter was used as an internal control. The 
data was normalized for the value in 22Rv1, and is shown as an 
average with standard deviation.Oncotarget 2011; 2:  358 - 362 361 www.impactjournals.com/oncotarget
that before the role of XMRV in the biology of 22Rv1 has 
been clarified, the implications of the studies conducted 
on this cell line should be treated with great caution. 
In conclusion, the lack of detectable presence of 
XMRV in CWR22 xenograft argues that the virus was 
also absent in the original tumor, and its presence in 
22Rv1 is an artifact. While the involvement of XMRV 
in determining biological properties of 22Rv1 remains 
unknown, the clinical relevance of the findings in this 
model of prostate cancer warrants extra scrutiny.
MethoDs
Polymerase chain reaction
XMRV  DNA  was  amplified  using  XMRV2AS 
(GTCCCCCAACAAAGCCACTC) and XMRV2S 
(ATCTAATCCTCGCGCCTGCGTC) primers. 
Myogenin-Forward (GTTTCTGTGGCGTTGGCTAT) 
and Myogenin-Reverse (GGTCGGAAAGGGCTTGTT) 
primers were used to amplify a fragment of human 
myogenin promoter. End-point PCR was done using 
Cheetah Taq (Biotium) for 36 cycles (94° C for 30 s, 56° C 
for 30 s, 72° C for 45 s). For quantitative PCR, iQ SYBR 
Green Supermix (Bio-Rad) was used. The samples were 
cycled (94°C for 30 s, 56°C for 30 s, 72°C for 45 s) in My 
iQ Single Color Real-Time PCR Detection System (Bio-
Rad); and the results were processed using manufacturer’s 
software and the ddCt method.
single nucleotide polymorphism genotyping
SNP genotyping was performed using the 
MassARRAY Compact system (Sequenom) on a panel 
of 65 custom SNP assays designed using RealSNP and 
MassARRAY Assay Designer (Sequenom).  Briefly, the 
protocol involves PCR amplification of 10ng DNA using 
SNP specific primers, followed by a base extension reaction 
using the iPLEX Gold chemistry (Sequenom).  The final 
base extension products were treated and spotted on a 
384-pad SpectroCHIP (Sequenom) using a ChipSpotter 
LT nanodispenser (Samsung).  A MassARRAY Analyzer 
Compact MALDI-TOF MS (Sequenom) was used for 
data acquisition from the SpectroCHIP. The resultant 
genotypes were called using MassARRAY Typer Analyzer 
v4.0 (Sequenom).
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